The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 306 participants.

Also called NCT07359599

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose supportive care
Phase
Phase 4
Enrolled
  • 306 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07359599
  • EU CT 2025-522936-14-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07359599. Randomized; quadruple masking; primary purpose supportive care. Start 2026-01-27 (actual); primary completion 2028-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Impact of IV Iron on Exercise Capacity and Quality of Life in Pulmonary Hypertension
Acronym
IRON-PH
Condition
Iron Deficiency
Intervention (Drug)
Ferric Carboxymaltose (FCM)
Intervention (Drug)
Sodium Chloride (NaCl) 0.9 %
Lead sponsor
Ziekenhuis Oost-Limburg (class: other)
Collaborator
Federal Knowledge Centre (KCE) (class: not stated)

Record details

Record id
cardio:ct-nct07359599
Content hash
e2d08c6edbeda138331646872ccfd54f9a7e90e94d605bea025836f8067d9aa6